CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.40BCNY505.02M · vs all stocks (USD)
Revenue (TTM)
272.12MCNY40.47M · vs all stocks (USD)
Profit Margin
-7.06%vs Biotechnology peers
Beta
0.5480xvs all stocks
52-Week Change
-35.24%vs all stocks
Market Capitalization
3.40BCNY505.02M · vs all stocks (USD)
Enterprise Value
3.49BCNY519.15M · vs all stocks (USD)
Price to Sales (TTM)
13.16xvs Biotechnology peers
Price to Book (MRQ)
2.56xvs Biotechnology peers
Enterprise to Revenue
12.83xvs Biotechnology peers
Enterprise to EBITDA
69.86xvs Biotechnology peers
Gross Margin
63.25%vs Biotechnology peers
Profit Margin
-7.06%vs Biotechnology peers
Operating Margin
-3.64%vs Biotechnology peers
Return on Assets (TTM)
-1.07%vs Biotechnology peers
Return on Equity (TTM)
-1.65%vs Biotechnology peers
Revenue (TTM)
272.12MCNY40.47M · vs all stocks (USD)
Revenue per Share (TTM)
0.6680CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-20.50%vs Biotechnology peers
Gross Profit (TTM)
157.04MCNY23.35M · vs all stocks (USD)
EBITDA (TTM)
60.30MCNY8.97M · vs all stocks (USD)
Net Income (TTM)
-19.21MCNY-2.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.58%vs Biotechnology peers
Operating Cash Flow (TTM)
21.56MCNY3.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.27MCNY338.06K · vs all stocks (USD)
5-Year Average Dividend Yield
0.90%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
9.85MCNYFY2025 · Dec 31, 2025Revenue
288.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
124.47MCNYFY2025 · Dec 31, 2025Gross Profit
163.79MCNYFY2025 · Dec 31, 2025Operating Income
-14.23MCNY-2.12M · vs all stocks (USD)
Pre-tax Income
-26.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
-1.34MCNYFY2025 · Dec 31, 2025Net Income
-24.97MCNYFY2025 · Dec 31, 2025EBIT
-25.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
60.30MCNYFY2025 · Dec 31, 2025Research & Development
44.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
80.03MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
625.11KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
532.06KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
409.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
409.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-24.97MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.48MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-59.34MCNYFY2025 · Dec 31, 2025Free Cash Flow
-104.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
91.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-24.97MCNYFY2025 · Dec 31, 2025Other Non-cash Items
580.99KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-34.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-727.70KCNYFY2025 · Dec 31, 2025Capital Expenditures
-44.72MCNYFY2025 · Dec 31, 2025Purchase of Investments
-598.00MCNYFY2025 · Dec 31, 2025Sale of Investments
593.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-49.16MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.12MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-265.69KCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.51MCNYFY2025 · Dec 31, 2025Shares Outstanding
410.64MSharesUpdated Aug 21, 2026Float Shares
219.40MSharesUpdated Aug 21, 2026% Held by Insiders
55.62%vs all stocks
% Held by Institutions
2.71%vs all stocks
Total Cash (MRQ)
83.29MCNY12.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2050CNYUpdated Aug 21, 2026Total Debt (MRQ)
14.09MCNY2.09M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0101xvs Biotechnology peers
Current Ratio (MRQ)
4.00xvs Biotechnology peers
Book Value per Share (MRQ)
3.41CNYUpdated Aug 21, 2026Total Assets
1.54BCNY229.37M · vs all stocks (USD)
Total Current Assets
535.90MCNYFY2025 · Dec 31, 2025Total Liabilities
143.41MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
10.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
133.33MCNYFY2025 · Dec 31, 2025Cash
91.57MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
122.00MCNYFY2025 · Dec 31, 2025Other Short-term Investments
32.82MCNYFY2025 · Dec 31, 2025Accounts Receivable
282.11MCNYFY2025 · Dec 31, 2025Inventory
94.47MCNYFY2025 · Dec 31, 2025Accounts Payable
16.43MCNYFY2025 · Dec 31, 2025Short-term Debt
13.26MCNYFY2025 · Dec 31, 2025Other Current Liabilities
8.63MCNYFY2025 · Dec 31, 2025Long-term Debt
915.79KCNYFY2025 · Dec 31, 2025Common Stock (Book)
410.64MCNYFY2025 · Dec 31, 2025Retained Earnings
384.23MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.40BCNY208.04M · vs all stocks (USD)
Treasury Stock
20.00MCNYFY2025 · Dec 31, 202552-Week Low
7.29CNYUpdated Aug 21, 202652-Week High
15.00CNYUpdated Aug 21, 202652-Week Change
-35.24%vs all stocks
Beta
0.5480xvs all stocks
50-Day MA
8.64CNYUpdated Aug 21, 2026200-Day MA
9.00CNYUpdated Aug 21, 2026Avg 10-Day Volume
5.43MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0400CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: -0.07
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk